RNA结合蛋白异质核糖核蛋白U降低提高多发性骨髓瘤对来那度胺的敏感性
多发性骨髓瘤(MM)中,来那度胺(LEN)耐药常见。研究发现异质核糖核蛋白U(hnRNPU)通过调控靶mRNA翻译影响MM对LEN的耐药性:hnRNPU低表达的MM细胞CRBN和IKZF1蛋白上调,LEN加入后IKZF1/3蛋白降解更严格,对LEN敏感性增加。RNA下拉实验和RNA电泳迁移率变动实验显示hnRNPU结合CRBN和IKZF1 mRNA的3‘非翻译区,蔗糖梯度实验提示hnRNPU特异性调控其翻译。小RNA竞争结合恢复MM对LEN的敏感性,免疫健全MM小鼠模型证实hnRNPU体内功能。
要点
- hnRNPU低表达的MM细胞中CRBN和IKZF1蛋白上调,对来那度胺敏感性增加。
- hnRNPU结合CRBN和IKZF1 mRNA的3’非翻译区,特异性调控其翻译。
- 小RNA竞争hnRNPU结合位点可恢复MM对来那度胺的敏感性。
核心结论
- 本研究提示hnRNPU通过抑制CRBN和IKZF1 mRNA翻译,影响多发性骨髓瘤对来那度胺的敏感性。
研究设计与样本
- 研究采用MM细胞系、RNA下拉实验、RNA电泳迁移率变动实验、蔗糖梯度实验,并在免疫健全MM小鼠模型中验证hnRNPU功能。
主要发现
- hnRNPU低表达的MM细胞CRBN和IKZF1蛋白上调,来那度胺加入后IKZF1/3蛋白降解更严格,对来那度胺敏感性增加。
- hnRNPU结合CRBN和IKZF1 mRNA的3‘非翻译区,蔗糖梯度实验提示hnRNPU特异性调控CRBN和IKZF1 mRNA翻译。
- 小RNA竞争hnRNPU与其靶mRNA结合可恢复MM对来那度胺的敏感性。
- 在免疫健全MM小鼠模型中证实了hnRNPU的体内功能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is an incurable plasma cell cancer in the bone marrow. Immunomodulatory drugs, such as lenalidomide (LEN) and pomalidomide, are backbone agents in MM treatment, and LEN resistance is commonly seen in the MM clinic. In this study, we presented that heterogeneous nuclear ribonucleoprotein U (hnRNPU) affected MM resistance to LEN via the regulation of target mRNA translation. hnRNPULow MM cells exhibited upregulated CRBN and IKZF1 proteins, stringent IKZF1/3 protein degradation upon LEN addition and increased sensitivity to LEN. RNA pulldown assays and RNA electrophoretic mobility shift assays revealed that hnRNPU bound to the 3'-untranslated region of CRBN and IKZF1 mRNA. A sucrose gradient assay suggested that hnRNPU specifically regulated CRBN and IKZF1 mRNA translation. The competition of hnRNPU binding to its target mRNAs by small RNAs with hnRNPU-binding sites restored MM sensitivity to LEN. hnRNPU function in vivo was confirmed in an immunocompetent MM mouse model constructed by the inoculation of Crbn-humanized murine 5TGM1 cells into CrbnI391V/+ mice. Overall, this study suggests a novel mechanism of LEN sensitivity in which hnRNPU represses CRBN and IKZF1 mRNA translation.
引用
- Lin Z, Zhang Y, Liu X, et al. Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide. Br J Haematol. 2024. PMID: 38685577. doi:10.1111/bjh.19468
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。